Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended July 31, 2000.
Business Overview: Cooper develops, manufactures, and markets healthcare products through two primary segments: CooperVision (CVI), specializing in contact lenses, and CooperSurgical (CSI), focusing on women's healthcare diagnostic and surgical products.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended July 31, 2000 |
9 Months Ended July 31, 2000 |
|---|---|---|
| Net Sales | $50,908 | $142,081 |
| Gross Profit | $33,500 | $92,616 |
| Gross Margin | 66% | 65% |
| Income from Operations | $13,049 | $32,666 |
| Net Income | $8,661 | $19,819 |
| Diluted EPS (Continuing Ops) | $0.59 | $1.40 |
| Cash from Operating Activities | N/A (Quarterly) | $28,407 |
| Cash and Cash Equivalents | $9,428 | $9,428 |
| Total Debt | $53,417 | $53,417 |
| Working Capital | $58,569 | $58,569 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% ($7.5 million) for the quarter and 18% ($22 million) for the nine-month period compared to the prior year.
- Segment Performance:
- CooperVision (CVI): Revenue grew 9% (quarter) and 11% (nine months), driven by 15% growth in U.S. core business and strong performance in disposable-planned replacement (DPR) toric and spherical lenses.
- CooperSurgical (CSI): Revenue surged 56% (quarter) and 50% (nine months), primarily due to the acquisitions of BEI Medical Systems and Leisegang Medical products.
- Profitability: Operating income rose 20% for the quarter and 24% for the nine-month period. Gross margins improved by one percentage point to 66% (quarter) and 65% (nine months), aided by cost reductions at CVI.
- Debt Reduction: Total debt decreased from $62.0 million (Oct 31, 1999) to $53.4 million (July 31, 2000) through refinancing and repayments, reducing interest expense by 12% (quarter) and 23% (nine months).
Guidance, Outlook, Risks, and Unusual Items
Unusual Items
- Settlement of Dispute: A $653,000 charge was recorded in the third quarter for a settlement with a German distributor, including a write-off of a joint venture investment.
- Accounting Change: A $432,000 after-tax charge was recorded in the first quarter for the cumulative effect of adopting SOP 98-5 regarding start-up activities.
- Tax Settlement: A $3 million payment settled a long-standing dispute with the California Franchise Tax Board, resulting in a reversal of previously reserved amounts.
Outlook and Guidance
- Tax Rate: Management estimates the effective tax rate for fiscal year 2000 will be 33% excluding unusual items, with a long-term target of approximately 30% over the next six years.
- Liquidity: The company expects cash on hand ($9.4 million) and operating cash flow to fund operations, capital expenditures, and smaller acquisitions. A $31.3 million line of credit remains available.
- Stock Repurchase: On August 30, 2000, the Board authorized the repurchase of up to one million shares of common stock.
Risks
- Foreign Exchange: Exposure to currency fluctuations, particularly the British pound, though most debt is hedged.
- Acquisition Integration: Risks associated with integrating recent acquisitions (BEI and Leisegang) and potential dilution from stock issuances.
- Environmental: An accrued liability of approximately $400,000 exists for groundwater remediation at a CVI site; management does not expect costs to be material beyond this amount.
Investor Verification Checklist
- Acquisition Impact: Verify the integration progress and margin trajectory of the BEI and Leisegang acquisitions, which drove CSI revenue growth but initially lowered segment margins.
- Cash Flow Sustainability: Confirm the ability to maintain positive operating cash flow in future quarters, noting the shift from historical first-quarter outflows.
- Debt Structure: Review the terms of the refinanced debt and the utilization of the KeyBank line of credit to ensure liquidity remains sufficient for the new stock repurchase program.
- Tax Provisions: Monitor the realization of the projected 30% long-term effective tax rate and the utilization of net operating losses (NOLs).
- Product Mix: Assess the continued growth of high-margin disposable-planned replacement (DPR) lenses at CVI versus the decline in lower-margin OEM sales.